Reduce elevated total-C, LDL-C, non-HDL, Apo B and triglycerides levels and to increase HDL-C in patients with homozygous familial hypercholesterolemia and mixed dyslipidemia as adjunct to diet and other non-pharmacological or lipid lowering treatments (eg, LDL apheresis) or if such treatments are unavailable or inadequate. As adjunct to diet for the treatment of patients with elevated serum triglyceride levels (hypertriglyceridemia/Fredrickson Type IV).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
